These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 13810671)

  • 1. [Comparison of coagulation time obtained with the one-stage method according to Quick (prothrombin time) and according to Owren (prothrombin-proconvertin time) in the control of coumarin treatment].
    CLETON FJ
    Ned Tijdschr Geneeskd; 1959 Sep; 103():1835-6. PubMed ID: 13810671
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of laboratory methods for the control of anticoagulant therapy with prothrombinopenic agents. I. The Quick one-stage procedure, the prothrombin and proconvertin test and the one-stage determination of true prothrombin activity.
    RODMAN T; PASTOR BH; FAWCETT KC
    Am J Med; 1961 Oct; 31():547-54. PubMed ID: 14493137
    [No Abstract]   [Full Text] [Related]  

  • 3. Control of anticoagulant therapy. A comparison of the thrombotest, the prothrombin-proconvertin method, and the prothrombin time.
    FICHERA C
    Acta Med Scand; 1962 Sep; 172():363-7. PubMed ID: 13945019
    [No Abstract]   [Full Text] [Related]  

  • 4. COUMARIN THERAPY. PROTHROMBIN ACTIVITY AFTER TERMINATION OF TREATMENT.
    REILLY EB; GOODMAN JR; WARNER GF
    Calif Med; 1963 Oct; 99(4):234-5. PubMed ID: 14051485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of dicumarol therapy by means of a micromethod for the quantitative determination of plasma prothrombin and proconvertin.
    LUND E; DYGGVE H
    Acta Med Scand; 1954; 150(4):271-5. PubMed ID: 13217722
    [No Abstract]   [Full Text] [Related]  

  • 6. [Analytical study on Quick test; determination of prothrombin, proconvertin, and proaccelerin].
    SOULIER JP; LARRIEU MJ
    Sang; 1952; 23(7):549-59. PubMed ID: 13004906
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tromexan and marcoumar in anticoagulant therapy; micromethod for determination of prothrombin-proconvertin activity].
    IVERSEN T
    Ugeskr Laeger; 1955 Jul; 117(27):873-8. PubMed ID: 13256759
    [No Abstract]   [Full Text] [Related]  

  • 8. Anticoagulant therapy with tromexan and marcoumar and determination of the prothrombin-proconvertin activity by a micro-method.
    IVERSEN T
    Acta Med Scand; 1956 Sep; 155(3):161-70. PubMed ID: 13361829
    [No Abstract]   [Full Text] [Related]  

  • 9. [Owren's method for quantitative prothrombin-proconvertin determination in control of anticoagulant therapy].
    LUND E
    Ugeskr Laeger; 1953 May; 115(21):801-5. PubMed ID: 13077997
    [No Abstract]   [Full Text] [Related]  

  • 10. A study of the relationship of concentrations of prothrombin, proconvertin, and proaccelerin to three methods for measuring prothrombin time.
    GONYEA LM; HJORT P; OWREN PA
    J Lab Clin Med; 1956 Oct; 48(4):624-33. PubMed ID: 13367602
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the prothrombin-proconvertin determinations (Owren-Aas) with prothrombin-index obtained with the Larsen-Plum prothrombin time method.
    LUND E; GEILL T; SØNDERGAARD E; DAM H
    Scand J Clin Lab Invest; 1955; 7(1):69-74. PubMed ID: 14396286
    [No Abstract]   [Full Text] [Related]  

  • 12. Prothrombin and proconvertin in the newborn and during the first year of life.
    DYGGVE H
    Acta Paediatr (Stockh); 1958 May; 47(3):251-9. PubMed ID: 13532682
    [No Abstract]   [Full Text] [Related]  

  • 13. The blood coagulation mechanism with especial reference to the prothrombin-proconvertin contents of plasma during long-term ACTH or cortisone therapy.
    FISCHER F; LUND E
    Acta Med Scand; 1954; 149(3):179-85. PubMed ID: 13180225
    [No Abstract]   [Full Text] [Related]  

  • 14. SURVIVAL TIME OF PROTHROMBIN AND FACTORS VII, IX AND X AFTER COMPLETELY SYNTHESIS BLOCKING DOSES OF COUMARIN DERIVATIVES.
    HELLEMANS J; VORLAT M; VERSTRAETE M
    Br J Haematol; 1963 Oct; 9():506-12. PubMed ID: 14076133
    [No Abstract]   [Full Text] [Related]  

  • 15. The influence of ACTH on prothrombin-proconvertin values in blood during treatment with dicumarol and phenylindanedione.
    HELLEM AJ; SOLEM JH
    Acta Med Scand; 1954; 150(5):389-93. PubMed ID: 13217736
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies of prothrombin and proconvertin (SPCA); concentrations in plasma of patients with pernicious anemia in remission, treated with vitamin B12.
    VETNE G; AXELROD AR
    Am J Clin Pathol; 1954 Jul; 24(7):796-801. PubMed ID: 13171349
    [No Abstract]   [Full Text] [Related]  

  • 17. Behaviour of factors II, VII, IX and X during long-term treatment with coumarin.
    LOELIGER EA; van der ESCH ; MATTERN MJ; den BRABANDER AS
    Thromb Diath Haemorrh; 1963 Apr; 9():74-89. PubMed ID: 13931274
    [No Abstract]   [Full Text] [Related]  

  • 18. ANTICOAGULANT THERAPY--BOON OR BANE?
    CELANDER DR; CELANDER E; MARTIN CG
    J Am Osteopath Assoc; 1964 Dec; 64():359-65. PubMed ID: 14233113
    [No Abstract]   [Full Text] [Related]  

  • 19. EXCHANGE TRANSFUSION IN HEREDITARY FACTOR VII (PROCONVERTIN) DEFICIENCY.
    HOFFMAN GC; HEWLETT JS
    Am J Clin Pathol; 1965 Aug; 44():198-202. PubMed ID: 14323496
    [No Abstract]   [Full Text] [Related]  

  • 20. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin.
    OWREN PA; AAS K
    Scand J Clin Lab Invest; 1951; 3(3):201-8. PubMed ID: 14900966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.